TRINETRA › Sectors › Healthcare
Cohance Lifesciences Limited (COHANCE) — share price, P/E and fundamentals
Cohance Lifesciences Limited (NSE: COHANCE) closed at ₹444.30 on 30 Oct 2026, -50.1% over one year, against a 52-week range of ₹266.70 – ₹917.85.
In the quarter ended 30 Jun 2026 (consolidated, filed 5 Aug 2026) it reported revenue of ₹422 cr and a net loss of ₹24 cr, a -5.7% net margin; revenue fell 23.1% year on year.
On four consecutive filed quarters its trailing P/E is 160.0; since 28 May 2025 its own P/E has ranged from 48.5 to 172.4 (median 97.6), and today's reading is higher than 88% of those 352 trading days.
From the balance sheet dated 31 Mar 2026: return on equity -2.5%, ROCE -2.8%, debt-to-equity 0.04, Piotroski F-score 5 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 2% of 63 sector peers; PBT margin higher than 2% of 63 sector peers; ROE higher than 3% of 63 sector peers.
Key figures
| Last close | ₹444.30 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -2.2% / +23.4% / -50.1% |
| 52-week low – high | ₹266.70 – ₹917.85 |
| Market capitalisation | ₹16,999 cr |
| Trailing P/E | 160.0 |
| Price / book | 4.35 |
| EV / EBITDA | 52.4 |
| Earnings yield | 0.6% |
| TTM EPS | ₹2.78 |
| TTM net profit | ₹106 cr |
| Quarter revenue | ₹422 cr |
| Quarter net loss | ₹24 cr |
| Net margin | -5.7% |
| Revenue growth (YoY) | -23.1% |
| Return on equity | -2.5% |
| ROCE | -2.8% |
| Debt / equity | 0.04 |
| Current ratio | 2.78 |
| Free cash flow | ₹148 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹30.7 cr |
Against Healthcare peers
| Metric | COHANCE | Peer median | Percentile |
|---|---|---|---|
| Net margin | -5.71 | 12.89 | 2 |
| PBT margin | -10.15 | 17.68 | 2 |
| ROE | -2.47 | 13.87 | 3 |
| ROCE | -2.84 | 17.26 | 3 |
| Debt / equity | 0.04 | 0.11 | 38 |
| Cash conversion | 2.45 | 1.25 | 90 |
| Trailing P/E | 160.02 | 43.07 | 98 |
| P/B | 4.35 | 6.02 | 33 |
Questions
What is the P/E ratio of Cohance Lifesciences Limited?
Cohance Lifesciences Limited's trailing P/E is 160.0, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 28 May 2025 its P/E has ranged 48.5–172.4.
What were Cohance Lifesciences Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Cohance Lifesciences Limited reported revenue of ₹422 cr and a net loss of ₹24 cr (consolidated), filed with the exchange on 5 Aug 2026.
What is Cohance Lifesciences Limited's ROE?
Return on equity is -2.5% based on the balance sheet dated 31 Mar 2026.
Does Cohance Lifesciences Limited have debt?
Debt-to-equity is 0.04 on the balance sheet dated 31 Mar 2026.
What is COHANCE's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, COHANCE traded between ₹266.70 and ₹917.85.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.